Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 101

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 101
---
 the collecting tubules. Scale bar, 100 µm. N = 6. C) Pretreatment with PHAD reduced tubular injury in a dose dependent manner as visualized (PAS). Source: Hernandez A, Patil N, et. al. Pretreatment with a novel Toll -like receptor 4 agonist attenuates renal ischemia -reperfusion injury. American Journal of Physiology -Renal Physiology 2023 324:5, F472 – F482 63 PHAD Pretreatment Reduces AKI in a Bilateral Ischemia / Reperfusion Model Mice were pretreated with intravenous PHAD at 200 µg/mouse or vehicle control, 48 and 24 hours prior to undergoing bilateral renal pedicle clamping for 24 minutes. A) Blood was analyzed for BUN and creatinine at baseline (0), and post -injuryday 1 and 3. Results expressed as means +/ -SEMwith N = 10. Two -wayANOVA was used to evaluate between group differences over time (p <0.05 for both BUN and serum creatinine), with p values shown after Sidak’s correction for multiple post hoc between group comparisons at each time point; B) Tubular injury scores in the outer stripe of the outer medulla from PAS -stainedsections Day 3 after injury; C) Apoptosis in the outer stripe of the outer medulla from TUNEL stained sections Day 3 after injury. N = 6 -7. Source: Hernandez A, Patil N, et. al. Pretreatment with a novel Toll -like receptor 4 agonist attenuates renal ischemia -reperfusion injury. American Journal of Physiology -Renal Physiology 2023 324:5, F472 – F482. Clinical Development Plan During 2024 we conducted a Phase 1 clinical study. Subsequently, safety and biomarker activity data from our Phase 1 clinical study was announced in June of 2024, showing a significant increase in anti -inflammatorycytokines including IL -1RAand IL -10. In January of 2025 we announced the start of our Phase 1b clinical study in CKD patients. The Phase 1b clinical study will support further development of Gemini -AKI. We expect data from our Phase 1b clinic study in the first half of this year. The Phase 1b study in CKD patients will be followed by a Phase